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Purpose: Continuous efforts into the discovery and development of new antimalarials are
required to face the emerging resistance of the parasite to available treatments. Thus, new
effective drugs, ideally able to inhibit the Plasmodium life-cycle stages that cause the disease
as well as those responsible for its transmission, are needed. Eight compounds from the
Medicines for Malaria Venture (MMV) Malaria Box, potentially interfering with the parasite
polyamine biosynthesis were selected and assessed in vitro for activity against malaria
transmissible stages, namely mature gametocytes and early sporogonic stages.
Methods: Compound activity against asexual blood stages of chloroquine-sensitive 3D7 and
chloroquine-resistant W2 strains of Plasmodium falciparum was tested measuring the para-
site lactate dehydrogenase activity. The gametocytocidal effect was determined against the
P. falciparum 3D7elo1-pfs16-CBG99 strain with a luminescent method. The murine
P. berghei CTRP.GFP strain was employed to assess compounds activities against early
sporogonic stage development in an in vitro assay simulating mosquito midgut conditions.
Results: Among the eight tested molecules, MMV000642, MMV000662 and MMV006429,
containing a 1,2,3,4-tetrahydroisoquinoline-4-carboxamide chemical skeleton substituted at
N-2, C-3 and C-4, displayed multi-stage activity. Activity against asexual blood stages of
both strains was confirmed with values of IC50 (50% inhibitory concentration) in the range of
0.07–0.13 µM. They were also active against mature stage V gametocytes with IC50 values
below 5 µM (range: 3.43–4.42 µM). These molecules exhibited moderate effects on early
sporogonic stage development, displaying IC50 values between 20 and 40 µM.
Conclusion: Given the multi-stage, transmission-blocking profiles of MMV000642,
MMV000662, MMV006429, and their chemical characteristics, these compounds can be
considered worthy for further optimisation toward a TCP5 or TCP6 target product profile
proposed by MMV for transmission-blocking antimalarials.
Keywords: Plasmodium, multi-stage antimalarials, transmission blocking drugs, malaria
elimination
Introduction
Despite huge efforts to reduce malaria transmission, the parasitic disease caused by
Plasmodium species continues to be a global health burden. Estimated 217 million
cases and 435,000 deaths occurred worldwide in 2017.1 Most malaria cases and
deaths were registered in Sub-Saharan Africa (90%). Whereas substantial control
achievements have been obtained over the last decade, no significant progresses in
reducing case incidence were made in all World Health Organization (WHO)
Regions between 2015 and 2017. Over the same period, the mortality rates also
stalled or decreased slightly according to the country.1
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The success of malaria control is essentially determined
by the availability of funding and the socio-economic condi-
tions of endemic countries. It is also well known that the
parasite itself, with its complex biology involving a highly
anthropophilic mosquito vector, poses major challenges to
the development of durable and effective control tools.
P. falciparum, the most pathogenic and diffused human para-
site species, has developed resistance to all the antimalarial
drugs. The first chloroquine-resistant P. falciparum strains
emerged in 1960 in Thailand and diffused in Africa in the late
70ies, following the global malaria eradication program
launched by WHO in the 60ies and 70ies.2 Resistance to
sulfadoxine/pyrimethamine (SP) appeared in Thailand in
1967, the same year of its introduction in the country.
Similarly, resistance to mefloquine began to appear in Asia
in 1985 around the time the drug became widely available.2
Since the early 2000, WHO advocates artemisinin combina-
tion therapy (ACT) as first-line treatment for uncomplicated
malaria; however, initial reports of parasite resistance have
been published already in 2009 in Asia.2 ACTs have been
integral to the successes of the global malaria control and at
present are essential to maintain these achievements. Thus,
the recent updates from the WHO Global Malaria
Programme monitoring the emergence and the diffusion of
multidrug resistance against the artemisinin derivatives
(delayed response) and partner drugs in the Greater
Mekong Subregion are raising major concerns on the current
malaria chemotherapy strategies with ACTs.3 In Africa, arte-
misinin resistance has not been reported to date and first-line
ACTs remain efficacious for uncomplicated malaria in all
malaria-endemic settings.3
Efficacious malaria control is based on integrated stra-
tegies targeting the parasite in the human host, and mos-
quitoes responsible for its transmission. Currently,
therapeutic tools include: i. the treatment of uncomplicated
malaria cases with ACTs after confirmed diagnosis and
supplementation with a single dose of primaquine as
a gametocytocidal to reduce transmission; ii. intermittent
preventive treatment of malaria in pregnancy using SP; iii.
chemoprevention with SP + amodiaquine (AQ+SP) in
children in highly seasonal transmission areas and in
regions where P. falciparum strains are still sensitive to
both drugs. Vector control is mainly based on the use of
long-lasting insecticidal bed nets, which is, however,
threatened by the emergence and diffusion of Anopheles
populations resistant to synthetic pyrethroids.1
Thus, drugs not only are important to cure patients,
save lives and prevent malaria in individuals but are
essential public health tools to impact on the intensity of
malaria transmission, and thus reduce the overall burden
of malaria. In line with global frameworks from WHO and
the United Nations, Medicine for Malaria Venture
(MMV) – a product development partnership in the field
of antimalarial drug research and development – puts one
of its strategic focus on bringing forward new tools to
counteract resistance, reduce transmission, and ultimately
to achieve malaria elimination and help eradication.4
Based on an integrated drug development model, MMV
recently proposed to orient R&D efforts on two Target
Product Profiles (TPP) and six different Target Candidate
Profiles (TCP).5 Among them, TCP 5 and TCP 6 focus on
transmission-blocking drugs and TPP 1 defines drugs
(combinations) that are effective against resistant strains,
can cure clinical malaria, stop transmission and prevent
relapse in a single encounter.4
Transmission blocking drugs may target developing and
mature gametocytes in the blood circulation of the human
host, early sporogonic stages, namely gametes, zygotes and
ookinetes developing in the mosquito blood meal or may be
harmful to the mosquito vector itself (endectocides). Since
the metabolism of immature sexual stages (male and female
gametocytes) is largely similar to that of asexual
blood stages, they are susceptible to many classes of
schizonticides.6,7 Mature gametocytes, however, are metabo-
lically down-regulated and thus a much more difficult drug
target.8 By contrast, early sporogonic development involves
various life-cycle stages and biological processes (gamete
formation, fecundation and zygote formation, ookinete
maturation) with a wide range of molecular pathways offer-
ing potential drug targets.8 The same holds true for endecto-
cides, which, after being taken up with blood-feeding,
potentially may interfere with various biological processes
of the mosquito. Thus, ideally and practically more feasibly,
a curative, transmission-blocking treatment should contain
compounds capable of killing asexual blood stages as well as
immature and mature gametocytes. Drugs acting on early
sporogonic stages and endectocides need to display a very
long half-life given that mature gametocytes can remain in
circulation for more than 1 week9 and the feeding activity of
Anopheles populations extends even over much longer peri-
ods (weeks to months) which vary according to local trans-
mission patterns.
In order to accelerate antimalarial drug discovery and
development, MMV has created the Malaria Box, a group
of 400 compounds chosen out of 25,000 active on asexual
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blood stages. The Malaria Box was made available for free
to interested research laboratories.10
To contribute to the joint drug development efforts, we
considered the results of antiplasmodial screening of
Tanzanian medicinal plants reported by Malebo et al.11
Tetrahydroisoquinolines (THIQs) isolated from Annickia
kummeriae (Engl. & Diels) Setten & Maas (Annonaceae)
were found to be promising and druggable molecules.
THIQs isolated from A. kummeriae exhibited significant
antiplasmodial activity against chloroquine-resistant strain
of P. falciparum with IC50 ranging from 0.08 to 0.24 μg/
mL in vitro.11 THIQs inhibit the growth of P. falciparum
by affecting polyamine metabolism, in particular through
the upregulation of the key catabolic enzyme, spermidine/
spermine N1-acetyltransferase (SSAT).12 Polyamine-
biosynthetic enzymes are essential for the growth and
survival of malaria parasites and exhibit structural features
that differ significantly between the parasites and the
human host.13
The identified THIQs compounds are druggable small
molecules, according to Lipinski’s rule, with oral bioavail-
ability and drug-likeness indices.14–17 Literature review
indicated that THIQ is one of the privileged chemical
scaffolds, commonly found in nature, endowed good anti-
plasmodial and pharmacokinetic properties.18 On these
bases, to discover and develop novel malaria transmission-
blocking drugs, we selected eight THIQs and related com-
pounds from the Malaria Box, with confirmed in vitro
activity against asexual blood stages of P. falciparum
(IC50 values <150 nM) and potential inhibitors of poly-
amine biosynthesis as a drug target. All selected com-
pounds display favorable in vitro pharmacokinetics,
diverse chemical scaffolds and pharmacophores, good
medicinal chemistry and druggability characteristics.
Here, we report on the in vitro activity of the eight selected
compounds against mature (stage V) gametocytes and
early sporogonic stages and discuss further possible com-
pound development.
Materials and Methods
MMV Malaria Box Compounds
Eight compounds, five drug-like (MMV000662,
MMV006429, MMV019266, MMV665876, MMV006767,
MMV019266) and three probe-like (MMV000642,
MMV085583, MMV665827), were procured from MCULE
(Mcule Inc., Palo Alto, CA 94301, USA; https://mcule.com/).
The structures of the molecules are depicted in Figure 1 and
other information is given in Table 1.
The drug-like properties are theoretically confirmed
applying the rule-of-5-compliance on physicochemical
properties, the rule of thumb for compounds likely to
show acceptable oral absorption. These are the four phy-
sicochemical quantities that have been used to profile
molecules with regard to the likelihood of their becoming
effective oral drugs. The drug-like properties score is
based on rules derived by the filter proposed in H bond
donors (nHDon) ≤5, H-bond acceptors (N + O) in ≤10,
molecular weight (MW) ≤500 and AlogP ≤5.19
Each of the MMV compounds was profiled with
respect to the violation of Lipinski’s Rule of 5, N+O
(nitrogen count plus oxygen count), molecular weight,
the number of hydrogen-bond donors and AlogP. Any
compound that failed one or more of these filters was
eliminated from the drug-like set and assigned to the
probe-like category.20 Two compounds revealed 1 or 2
violation of the rule of five (Table 2).
In vitro Antiplasmodial Activity Against
P. falciparum Asexual Blood Stages
Maintenance of Plasmodium falciparum Strain W2 and
3D7
Two different strains of P. falciparum, W2 (chloroquine-
resistant) and 3D7 (chloroquine-sensitive), were used for
the chemosensitivity tests. The parasites were cultured
according to the method described by Trager and Jensen
with slight modifications.21 The parasites were cultured in
human type A-positive or type 0-positive erythrocytes at
5% hematocrit at 37°C in a standard gas mixture consist-
ing of 1% O2, 5% CO2, 94% N2. Medium was made up of
RPMI-1640 with the addition of 1% AlbuMax, 0.01%
hypoxanthine, 20mM Hepes and 2mM L-glutamine. For
routine parasite growth, the parasitemia was maintained
within 1% and 5%, and evaluated as the number of
infected RBC with respect to the total number counted,
in blood smears colored with Giemsa.
Drug Sensitivity pLDH Assay
For the drug sensitivity assay, the compounds were dis-
solved in DMSO and then diluted with medium to achieve
the required concentrations (final DMSO concentration
<1%, which is non-toxic to the parasite). The drugs were
placed in 96-wells flat-bottom microplates in duplicate and
seven 1:2 serial dilutions made directly in the plate in
a volume of 100 µL. Asynchronous cultures with
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a parasitemia of 1–1.5% and 2% hematocrit (1% final) were
aliquoted into the plates and incubated for 72 h, in a final
volume of 200 µL/well. Chloroquine was used as a reference
compound. Parasite growth was determined by measuring
the activity of the parasite lactate dehydrogenase (pLDH),
according to a modified version of Makler’s method.22 The
pLDH activity is distinguishable from the host LDH using
the 3-acetyl pyridine adenine dinucleotide (APAD) as co-
factor. Briefly, at the end of the incubation, the cultures were
carefully re-suspended, and aliquots of 20 µL were removed
and added to 100 µL of the Malstat reagent in a 96-well
microplate. The Malstat reagent is made of 0.125% Triton
X-100, 130 mM L-lactate, 30 mM Tris buffer and 0.62 µM
APAD. Twenty-five µL of 1.9 µM NBT (Nitro Blue
Tetrazolium) and 0.24 µM PES (phenazine ethyl sulphate)
were added to the Malstat reagent. NBT is reduced to blue
formazan and is spectrophotometrically (OD650) read as
a measure of pLDH activity and thus of parasite viability.
The results were expressed as the percent viability compared
to the untreated controls, calculated with the following
formula: 100× ([Readout of treated sample – blank]/
[Readout of untreated sample – blank]); Readout is OD
(Optical Density). As blank, uninfected RBC were used.
The percentage of viability was plotted as a function of
drug concentrations and the curve fitting was obtained by
nonlinear regression analysis using a four-parameter logistic
method (software Gen5 1.10 provided with the Synergy4
plate reader [Biotek]). The IC50, which is the dose capable of
inducing 50% inhibition of parasite viability, was obtained
by extrapolation.
In vitro Activity Against Plasmodium
falciparum Mature Gametocytes
P. falciparum Gametocyte Induction
The transgenic P. falciparum 3D7 strain 3D7elo1-pfs16-
CBG99 expressing the Pyrophorus plagiophthalamus
CBG99 luciferase under a gametocyte-specific promoter
was used for chemosensitivity assay on gametocytes.
Parasites were cultured and gametocytes obtained as
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Figure 1 Chemical structures of the eight selected Malaria Box compounds taken from Pubmed open chemistry database.
Malebo et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Drug Design, Development and Therapy 2020:141596
previously described.23 Late-stage gametocytes were
exposed to compounds at day 11 after N-acetylglucosamine
(NAG) addition. Gametocytes stages were counted in
Giemsa stained smears and the percentages of stage
V gametocytes were higher than 80%.
Gametocyte Drug Susceptibility Assay
Compounds were prepared by serial dilution, in 96-well
plate, in the complete medium as described for asexual para-
sites. Methylene blue and dihydroartemisinin were used as
reference drugs. After 72 h incubation, luciferase activity
was taken as a measure of gametocytes viability, as pre-
viously described.24 Briefly, drug-treated gametocytes at
2% haematocrit were transferred to 96-well black micro-
plates and D-luciferin (1 mM in citrate buffer 0.1 M, pH
5.5) was added at a 1:1 volume ratio. Luminescence mea-
surements were performed after 10 min with 500 ms integra-
tion time using a Sinergy 4 (Biotek) microplate reader. The
IC50 was calculated as described for asexual parasites, being
the readout for gametocytes ALU (Arbitrary Luminescent
Units). As a blank, gametocytes treated with a high dose of
MB (300 ng/mL) were used.
Table 1 Information on the Eight Malaria Box Compounds Procured by MCULE
Mcule ID MMV
Code
Classification Systematic Name Molecular
Weight
(MW)
Minimal
Purity
(%)
MCULE-4901923747 MMV000662 Drug-like N-(4-methoxyphenyl)-2-(2-methylpropyl)-1-oxo-
3-(thiophen-2-yl)-1,2,3,4-tetrahydroisoquinoline-
4-carboxamide
434.552 90
MCULE-8458142469 MMV006429 Drug-like N-(5-methyl-1,2-oxazol-3-yl)-2-(2-methylpropyl)-1-oxo-
3-(thiophen-2-yl)-1,2,3,4-tetrahydroisoquinoline-
4-carboxamide
409.502 90
MCULE-6374215881 MMV000642 Probe-like N-(3-chloro-4-methoxyphenyl)-2-(2-methylpropyl)-1-oxo-
3-(thiophen-2-yl)-1,2,3,4-tetrahydroisoquinoline-
4-carboxamide
468.995 90
MCULE-1940445307 MMV019266 Drug-like 2-({5,6-dimethylthieno[2,3-d]pyrimidin-4-yl}sulfanyl)-1H-
1,3-benzodiazole
312.415 90
MCULE-6989044901 MMV665876 Drug-like 6-(1-phenylpropyl)-3-(thiophen-2-yl)-[1,2,4]triazolo[3,4-b]
[1,3,4]thiadiazole
326.444 90
MCULE-4456901740 MMV006767 Drug-like 2-amino-6,7-dimethoxy-N-phenylquinoline-3-carboxamide 323.345 90
MCULE-5171532492 MMV085583 Probe-like (3R,11R)-3-(3,4-Dimethoxyphenyl)-10-hexanoyl-11-[4-
(trifluoromethyl)phenyl]-2,3,4,5,10,11-hexahydro-1H-
dibenzo[b,e][1,4]diazepin-1-one
592.646 90
MCULE-1785799097 MMV665827 Probe-like ethyl 1-ethyl-6-fluoro-4-oxo-7-(piperidin-1-yl)-
1,4-dihydroquinoline-3-carboxylate
346.395 90
Note: Malaria Box Compounds as described in Van Voorhis et al.10
Abbreviation: MMV, Medicines for Malaria Venture.
Table 2 Drug Like Properties of the Eight Malaria Box Compounds
Malaria Box Compound Ro5_Violation Count N Plus O_Count Molecular Weight Num_H_Donors ALogP
1. MMV000662 0 5 434.55054 1 4.427
2. MMV006429 0 6 409.50132 1 3.582
3. MMV000642 1 5 468.9956 1 5.092
4. MMV019266 0 4 312.41258 1 4.458
5. MMV665876 0 4 326.43915 0 4.285
6. MMV006767 0 6 323.34587 2 2.56
7. MMV085583 2 6 592.6479 1 7.336
8. MMV665827 0 5 346.39592 0 3.364
Notes: Ro5_Violation Count = Violation of Lipinski’s Rule of 5; eg 1=1 violation of Lipinski’s rule; N plus O Count = Sum of Nitrogen and Oxygen atoms; Num_H_Donors = Sum
of hydrogen-bond donors in the molecule; ALogP = Calculated partition coefficient.
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Activity Against Early Sporogonic
Development in vitro on Plasmodium
berghei Pb.CTRPp.GFP Strain
Plasmodium Strain
The P. berghei CTRPp.GFP strain, expressing GFP exclu-
sively at early sporogonic stages (ESS), namely in zygotes
and ookinetes, was used for the assessment of molecules’
activity against the development of ESS in vitro. The rodent
malaria parasite strain was maintained by mouse to mouse
acyclic and mouse to mosquito to mouse cyclic passages.
BALB/c mice and Anopheles stephensi mosquitoes were
employed as vertebrate and vector host, respectively.
Vertebrate Host for P. berghei CTRPP.GFP
Gametocyte Production
Eight- to ten-week-old BALB/c mice were used as game-
tocyte donors for the in vitro experiments. The mice were
reared in the animal house (24°C, 14 h light/10 h dark
cycle and 70% relative humidity), fed on standard mice
pellets (Mucedola s.r.l., Milano, Italy) and provided with
tap water ad-libitum. Experimental animal rearing and
handling were in compliance with the Italian Legislative
Decree on the “use and protection of laboratory animals”
(D. Lgs. 116 of 10/27/92) and in full adherence with the
European Directive (86/609) of 24/11/1986 (license no.
125/94A, issued by the Italian Ministry of Health). The
protocol was approved by the University Research Ethics
Committee of the University of Camerino – protection of
animals used for experimental and other scientific pur-
poses (protocol number: UREC_CAM_2017/19). The
experiments were in accordance with the protocols
approved by the Animal Ethics committee of the
University of Camerino.
Evaluation of Effects on Early Sporogonic Stages in vitro
The impact of MMV molecules on the development of ESS
was evaluated in the ookinete development assay.25 Parasite
infected BALB/c mice were used as a source of gametocytes
for the in vitro assay and obtained by the following procedure.
To stimulate erythropoiesis, mice were treated with phenylhy-
drazine (120 mg/kg i.p.) 4 days prior to infection with
P. berghei CTRPp.GFP through i.p. injection of 10
7 infected
RBCs. Gametocytemia was checked 4-days post-infection by
microscopic examination of thin blood films and the maturity
of microgametocytes verified by testing their capacity to gen-
erate flagellate microgametes in the exflagellation assay. In
brief, a drop of tail blood from a gametocytemic mouse was
diluted at a ratio of about 1:25 in exflagellationmedium (RPMI
1640 containing 25 mMHEPES, 25 mM sodium bicarbonate,
50 mg/L hypoxanthine, 100 μM xanthurenic acid, pH 8,3).
Then, 8 µL of the diluted blood sample was incubated and
examined in a hand-made coverslip/slide chamber consisting
of a slide as a base, 2 cover slips placed on it laterally as
spacers, and a third one placed on the top to close the chamber.
Then, all sides of the cover slip were sealed with a mixture of
Vaseline and Tween 80 (approximately 1:2 ratios). After 20
min incubation at 19° C, the slides were examined for exfla-
gellation centers under the microscope (400X magnification).
Mice with abundant exflagellation centers (more than 3 per
1000 red blood cells) were selected and used as blood donors
for the ookinete development assay. This assay allows to assess
effects ofmolecules on the sexual parasite stages developing in
the vector, namely male and female gametes, zygotes and
ookinetes, simulating in vitro the physicochemical conditions
of the mosquito midgut environment: 80 µL of ookinete med-
ium [exflagellation medium with 20% heat-inactivated foetal
bovine serum and 1% penicillin (10,000 U/mL)/streptomycin
(10,000 µg/mL) adjusted to pH 7.4] was added to the wells of
a 96-well microplate (Nunc, Denmark). Dimethyl Sulfoxide
(DMSO)was used as a solvent formolecules. Tenmicroliter of
diluted molecules was then added to the microplate wells
containing 80 µL of medium to obtain the desired test concen-
trations (12.5–100µM).DMSOat 0.2%was used as a negative
control. Then, 10 µL aliquots of blood obtained by cardiac
puncture from gametocytemic mice were transferred to the
microplate wells containing test products or solvent controls,
and mixed swiftly. The plates were then incubated at 19°C for
24 h. At the end of incubation, well contents were mixed and
5 µL cell suspension from each well was withdrawn and
diluted with PBS (pH=7.4) at about a ratio of 1:25 to 1:50 in
a separate 96-well microplate. This dilution step allowed to
obtain – after cell settlement – a monolayer of blood cells and
parasites, a condition that was required for an accurate micro-
scopic examination. GFP expressing zygotes and ookinetes
were visualized using a Zeiss fluorescent microscope (400
X magnification) and quantified with the help of an ocular
grid. Each molecule was examined in three replicate wells and
six wells were reserved for DMSO controls. Experiments were
repeated at least twice with different donor mice. The percent
inhibition of ESS development induced by the molecules was
calculated as follows:
Percent inhibition
of ESS development
¼ 1
Mean ESS count in test wells
Mean ESS count in solvent control wells
 
100
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Thin Blood Smear Preparation
In order to assess the morphological impact of active
compounds on zygotes and ookinetes, thin blood smears
were prepared from the plate wells at the end of the
ookinete assay. The MMV molecule treated wells were
compared with DMSO controls. Briefly, the content of
triplicate wells was transferred into an eppendorf tube
and centrifuged at 1500 rpm for 10 min. Thin blood
smears were prepared with the cell pellet, fixed with
methanol and stained with giemsa (10% in PBS pH 7.4)
for 90 mins. Smears were examined under the light micro-
scope (1000×magnification) and early sporogonic stages
counted over a slide area corresponding to 80,000 red
blood cells. Early sporogonic forms on treatment and
control slides were differentially counted as zygotes, retort
forms, fully matured ookinetes, denatured zygotes and
residual cells.
Statistical Analyses
Excel 2007 spreadsheet and GraphPad Prism 6 statistical
software (GraphPad Software, S. Diego, CA, USA) were
used for data analysis. Descriptive statistical tools were
also applied to express Early Sporogonic Stage counts and
% inhibition values as arithmetic means ± 95% confidence
intervals (95% CI).
Results
In vitro Activities of MMV Malaria Box
Compounds Against Asexual Stages of
P. falciparum
One of the selection criteria for the eight studied com-
pounds was high in vitro activity against asexual blood
stages (IC50 values below 0.150 µM), with the exception
of MMV006767 (6), that was included for its structural
characteristics although displaying only moderate activity
in previously published screening (Table 3). Compound 6
displayed moderate activity (IC50 > 2148 µM) also in this
study, whereas compounds 1, 2, 3, 7 and 8 confirmed IC50
values in the range of 0.100–0.300 µM against both CQ-S
and CQ-R P. falciparum strains remaining within the in-
between laboratory variability (Table 3). Compound 4
(MMV019266) was not active in our assay (IC50 >8 µM)
in contrast to the data obtained by the majority of other
groups (Table 3 and Van Voorhis et al 2016).10 The activ-
ity of four compounds (1-2-3-7) was better than CQ on the
CQ-resistant strains. None of the tested compounds
revealed a level of activity comparable to that of Ta
b
le
3
In
vi
tr
o
A
ct
iv
ity
of
In
ve
st
ig
at
ed
M
al
ar
ia
Bo
x
C
om
po
un
ds
A
ga
in
st
A
se
xu
al
Bl
oo
d
St
ag
es
of
W
2,
C
Q
-R
,a
nd
3D
7,
C
Q
-S
P.
fa
lc
ip
ar
um
St
ra
in
s
an
d
C
om
pa
ri
so
n
w
ith
D
at
a
in
th
e
Li
te
ra
tu
re
C
o
m
p
o
u
n
d
N
am
e
P.
fa
lc
ip
ar
um
A
se
xu
al
B
lo
o
d
S
ta
ge
s
IC
5
0
(µ
M
)
C
Q
-R
es
is
ta
n
t
S
tr
ai
n
s
C
Q
-S
en
si
ti
ve
S
tr
ai
n
s
W
2a
D
d
2b
W
2b
K
1b
K
1c
D
d
2d
F
C
R
3e
3D
7a
3D
7b
H
B
3b
3D
7f
3D
7f
3D
7f
3D
7g
1.
M
M
V
00
06
62
0.
13
3±
0.
06
9
0.
05
3
0.
04
9
0.
06
6
0.
07
4
1.
25
8
0.
12
0±
0.
05
0
0.
04
9
0.
05
8
0.
26
2
0.
37
0.
34
3
0.
03
7
2.
M
M
V
00
64
29
0.
13
2±
0.
03
8
0.
07
3
0.
07
7
0.
07
9
0.
03
9
0.
16
0.
07
4
0.
12
3±
0.
00
3
0.
06
2
0.
21
3
0.
38
5
0.
3
0.
03
3
3.
M
M
V
00
06
42
0.
07
0±
0.
00
2
0.
05
1
0.
04
6
0.
11
7±
0.
01
2
0.
02
4.
M
M
V
01
92
66
>
8
0.
07
9
0.
06
2
0.
15
3
0.
58
2
0.
84
4
0.
04
4
>
8
0.
05
8
0.
09
3
0.
62
5.
M
M
V
66
58
76
0.
69
0±
0.
04
8
0.
07
8
0.
06
0.
12
3
0.
91
6
0.
33
8
0.
15
8
0.
34
0±
0.
01
6
0.
12
9
0.
15
0.
18
1
0.
41
5
0.
26
6.
M
M
V
00
67
67
2.
14
8±
0.
03
1
0.
35
7
0.
79
7
1.
49
4
0.
88
4
0.
93
1
1.
02
0±
0.
31
9
0.
59
2
0.
81
2
0.
93
7.
M
M
V
08
55
83
0.
10
1±
0.
03
6
0.
24
5
0.
14
7
0.
08
2
0.
28
8
0.
17
9
0.
17
9
0.
17
1±
0.
04
5
0.
16
5
0.
20
0
0.
12
9
0.
14
4
0.
24
8.
M
M
V
66
58
27
0.
29
5±
0.
01
8
0.
06
3
0.
25
9
0.
27
6
0.
17
3±
0.
00
5
0.
16
5
0.
13
0
0.
12
D
H
A
0.
00
2±
0.
00
1
0.
00
2±
0.
00
1
C
Q
0.
30
4±
0.
13
8
0.
02
2±
0.
00
6
N
o
te
s:
a O
ri
gi
na
ld
at
a
fr
om
th
is
w
or
k.
M
ea
n
±
SD
of
at
le
as
t
tw
o
ex
pe
ri
m
en
ts
.b
–
g
D
at
a
w
er
e
ge
ne
ra
te
d
in
th
e
la
bo
ra
to
ri
es
of
A
yo
ng
,A
ve
ry
,H
or
ro
ck
s,
Va
n
Vo
or
hi
s
an
d
Po
ul
se
n
an
d
pu
bl
is
he
d
as
or
ig
in
al
da
ta
in
th
e
re
vi
ew
of
Va
n
Vo
or
hi
s
et
al
;
C
re
at
iv
e
C
om
m
on
s
C
C
O
pu
bl
ic
do
m
ai
n
de
di
ca
tio
n.
10
A
b
b
re
vi
at
io
n
s:
C
Q
,c
hl
or
oq
ui
ne
;D
H
A
,d
ih
yd
ro
ar
te
m
is
in
in
.
Dovepress Malebo et al
Drug Design, Development and Therapy 2020:14 submit your manuscript | www.dovepress.com
DovePress
1599
dihydroartemisinin (DHA), used as a positive control in
the assay.
In vitro Activity of MMV Malaria Box
Compounds Against Mature Stage
V Gametocytes
Among the eight screened MMV molecules, compounds 1,
2 and 3 (MMV000662, MMV006429, MMV000642),
showed IC50 values below 5 µM, ranging from 3.43 to
4.42, against stage V gametocytes (Table 4). Compound 6
(MMV006767) displayed IC50 values below 10 µM and
compounds 4, 5, 7 and 8 (MMV19266, MMV665876,
MMV085583, MMV665827) were not active (IC50
> 20µM). As shown in Table 4, these results are in good
agreement with other studies that examined the impact on
stage V gametocytes26–28 and to a lesser extend with those
that employed tests not discriminating gametocyte stage
IV and V.
Effects of MMV Malaria Box Compounds
on Early Sporogonic Stages
At a primary screening dosage of 50 µg/mL, inhibitory
effects on early sporogonic development were observed
with compounds 1, 2 and 3 (MMV000662, MMV006429,
MMV000642), the same compounds found to be active on
asexual stages and gametocytes. At this high dosage (corre-
sponding to the molar concentration of 115.06 µM, 122.10
µM, 106.61 µM for compounds 1, 2 and 3, respectively), the
number of early sporogonic stages (ESS), ie the total counts
of fluorescent zygotes, retort forms (early ookinete stage) and
elongated ookinetes, was reduced by 60% to 80% in wells
incubated with the three compounds (Figure 2). In addition,
differential counts of retort forms and elongated ookinetes
revealed inhibition of ookinete development (>80%) by com-
pounds 1, 2 and 3. Compounds 4 (MMV19266) and 7
(MMV085583) were not active, whereas compounds 5
(MMV665876), 6 (MMV006767) and 8 (MMV665827)
appeared to interfere with the ookinete development
(>60%), but not with the early sporogonic development
before zygote formation as reflected by the overall counts
of ESS (<20% inhibition). IC50 values estimated for com-
pounds 1, 2 and 3 were in the range of 30 to 40 µM indicating
an impact of the three compounds on ESS counts and con-
firming the activity of these compounds previously reported
(Table 5). 29 Just a slightly stronger effect of the three
compounds was observed on ookinete development, illu-
strated by IC50 values ranging from 19 to 29 µM (Table 5).
Effects of Malaria Box Compounds on
Early Sporogonic Stages’ Morphology
To assess whether the effects of Malaria Box compounds
on early sporogonic stages, evidenced in the ookinete
development assay (ODA), was accompanied by morpho-
logical alterations of the cells, Giemsa stained thin smears
were prepared from the ODA plates after treatment with
the compounds at 50 µg/mL.
On the slides prepared from compounds 1, 2 and 3
(MMV000662, MMV006429 and MMV000642), not
a single fully elongated ookinete could be found screening
120 optical fields at 1000x magnification (corresponding
to an area covered by a monolayer of 12,000–14,000 red
blood cells) (Table 6). For comparison, on the DMSO
control smear, 46 mature ookinetes and 30 retort forms
were observed among a total of 122 early sporogonic
forms. On the slides of compounds 1, 2 and 3, the few
ESS retrieved, showed various morphological alterations
such as irregular shape, jagged borders, enlarged hemozoin
vacuoles and absence of a condensed nucleus (Figure 3,
images G and H). On the slides of the cells treated with
compounds 5 and 6 (MMV665876, MMV006767), having
shown marginal activity against ESS and slight effects on
ookinete formation in the ODA, 34 and 33 early sporogo-
nic forms, respectively, were recorded, corresponding to
about one fourth of the control (122).
Notably, most of the observed cells were altered
zygotes or post-zygotic forms displaying alterations, as
illustrated above for compounds 1, 2 and 3 (Figure 3,
images E to H). The smear of compound 8 showed 91
ESS, but almost all of them displayed morphological
alterations of the zygotes or post-zygotic forms. In contrast
to the alterations observed on slides of compounds 1, 2, 3,
5 and 6, early sporogonic forms incubated with compound
8 displayed a centrally condensed nucleus (Figure 3,
images I to L).
Discussion
The purpose of this study was to evaluate the in vitro
efficacy of eight selected Malaria Box compounds, potential
inhibitors of polyamine biosynthesis, against different
stages of the Plasmodium parasite. The results from the
various stage-specific tests confirmed the activity of some
of these compounds against P. falciparum asexual blood
stages and gametocytes and against P. berghei early spor-
ogonic stages. Three out of the eight screened Malaria Box
compounds, namely compound 1 (MMV000662),
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compound 2 (MMV006429) and compound 3
(MMV000642), exhibited inhibitory effects against all the
three tested parasite stages, responsible for the disease and
for its transmission to the mosquito vector.
Four of these compounds (1, 2, 3 and 7) were active on
chloroquine-resistant and chloroquine-sensitive asexual
blood stages of P. falciparum, with IC50 values ranging
from 0.070 to 0.171 µM. Comparing the present results
with those of other studies presented in the Van Voorhis
meta-analysis of the total 400 Malaria Box compounds,
a high agreement emerges.10 In particular, looking at 12
studies that examined a majority of the eight herein consid-
ered compounds (please see Supporting Information S1
Table. Malaria Box HeatMap available online https://jour
nals.plos.org/plospathogens/article/file?type=supplementar
y&id=info:doi/10.1371/journal.ppat.1005763.s002; columns
from N to Q and from S to Z in Van Voorhis et al),10 a full
concordance appears in the case of compound 2 and 3, with
10/10 and 5/5 studies, respectively; an almost complete
match emerges also for compound 1, active in 9/10 studies
and still a good match was noted for compound 7 active in 7/
11 different reports.
Compounds 1, 2 and 3 resulted also to be the most
active against P. falciparum stage V gametocytes with IC50
values ranging from 3.3 to 4.4 µM. Comparison with
studies presented in the Van Voorhis review reveals
a clear concordance with tests specifically targeted on
mature stage V gametocytes, but a poor match with pro-
tocols that include both stage IV and V gametocytes
(please see Supporting Information S1 Table. Malaria
Box HeatMap columns from AU to CB in Van Voorhis
et al).10 Testing compounds 1, 2, and 3 at 12.5 µM on
stage V gametocytes, an inhibition in the range of 88 –
94% was observed by Winzeler and colleagues (S1 Table.
Malaria Box HeatMap,10 column BC)27 whereas inhibition
of gamete formation by stage V gametocytes from 40% to
78% was reported by Alano, Avery and colleagues (S1
Table. Malaria Box HeatMap,10 column BV)26 at 5 µM for
the same compounds. Moreover, compound 2 at 1 µM was
found to inhibit female and male gamete formation upon
exposure of stage V gametocytes.29
Regarding gametocyte stage IV and V inclusive tests,
according to the heat map analysis10 compound 3 was
active only in the Duffy & Avery study displaying a 66%
inhibition at 5 µM on stage IV–V gametocytes of the
NF54-pfs16GFP strain (S1 Table. Malaria Box
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Figure 2 Effects of the eight Malaria Box compounds (1 MMV000662, 2 MMV006429, 3 MMV000642, 4 MMV019266, 5 MMV665876, 6 MMV006767, 7 MMV085583, 8
MMV665827) on early sporogonic development of P. berghei CTRPp.GFP at a screening concentration of 50 µg/mL. Grey bars: impact (% inhibition in respect to DMSO
controls) on the formation of early sporogonic stages, counting all forms (zygotes, retort forms and fully elongated ookinetes); black bars: impact (% inhibition) on the
formation of ookinetes counting elongated forms (retorts, stumpy and fully elongated ookinetes). Vertical bars depict confidence intervals at 95%.
Table 5 IC50 Values of Malaria Box Compounds 1 MMV000662,
2 MMV006429 and 3 MMV000642 on Early Sporogonic Stages
and Ookinete Development and Comparison with Data in the
Literature
Compound
Name
IC50 (µM) [95% C.I.] P. berghei
Ookinete
Assay %
Inhibition at
10µMb
ESS
Inhibitiona
OD
Inhibitiona
1. MMV000662 30.8 [28.5–33.8] 19.0 [15–24.7] 100
2. MMV006429 39.8 [35.5–44.2] 26.4 [25.7–27.3] 94,1
3. MMV000642 34.1 [31.8–36.4] 29.1 [0.4–35.7] 80,8
Notes: aOriginal data from this work. bData from Rueker et al.29
Abbreviations: ESS, Early sporogonic stages; OD, Ookinete development.
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HeatMap,10 column BH).30 Slightly better concordance
with stage IV–V assays was seen with compound 5 that
resulted active in the studies of Duffy & Avery and
Taramelli and colleagues (S1 Table. Malaria Box
HeatMap,10 column BO and BP).30
Moving along the parasite life cycle to the insect spor-
ogonic development, again activity was found with com-
pounds 1, 2 and 3 (MMV000662, MMV006429 and
MMV000642) that inhibited 50% of early sporogonic
stages (ESS; including zygotes, retort forms, stumpy and
Table 6 Effects of Malaria Box Compounds on Early Sporogonic Stages
No. of Elongated
Ookinetes
No. of Retort
Forms
No. of
Zygotes
No. of Altered
ESSa
Total no. of ESS
Formsb
% ESS
Inhibition
DMSO control 46 30 24 22 122 0
1. MMV000662 0 0 0 2 2 98.4
2. MMV006429 0 0 0 9 9 92.6
3. MMV000642 0 0 0 5 5 95.9
5. MMV665876 0 0 0 34 34 72.0
6. MMV006767 0 1 4 28 33 73.0
8. MMV665827 0 1 1 89 91 25.5
Notes: aMorphologically altered zygotes and post-zygotic forms as illustrated in Figure 3. bCounts were obtained by reading 120 fields at 1000 x magnification at the optical
microscope, corresponding to a monolayer of 120 000 to 140 000 red blood cells.
Abbreviation: ESS, Early sporogonic stage.
Figure 3 Light microscopy images (1000x) from Giemsa stained P. berghei early sporogonic stages taken from ODA plates after 24 hrs of incubation in ookinete medium at
19°C. Upper row: images from DMSO control preparations, (A) zygotes, (B) Early retort form, (C) Stumpy ookinete, (D) Fully elongated ookinetes. Middle row: images
from Malaria Box compound 5 (MMV665876), (E) Zygote with enlarged hemozoin vacuole, (F) Zygote with enlarged hemozoin vacuole and absence of condensed nucleus,
(G and H) Post-zygotic forms with irregular shape, jagged borders, enlarged hemozoin vacuole and absence of condensed nucleus. Bottom row: images from Malaria Box
compound 8 (MMV665827), (I–L) Alterations as described in image (G and H) Except for the presence of condensed nuclei.
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elongated ookinetes) at 3.1, 39.1 and 40.3 µM, respec-
tively. These results indicate that the compounds interfere
with processes occurring before zygote formation, ie with
the development of macrogametes, microgametes and/or
fecundation. The same compounds have been previously
found to be active in the same assay with activities higher
than in this study by about a factor of 10 (S1 Table.
Malaria Box HeatMap,10 column from CD to CF).29 This
might be explained by differences in the assay protocol, or
in the mouse strain used as gametocyte donor (TO mice by
Delves/Sinden, Balb/C mice in this paper) or the method
of read out of the fluorescent parasites (plate spectrophot-
ometer by Ruecker et al versus microscope counts at 400x
magnification in this study).29 The plate spectrophoto-
metric read outs appear to overestimate ookinete numbers
by about a factor 2 when compared to the Giemsa slide
counts. Comparing the results of this study with other
literature data, the capacity of compounds 1 and 3 to
interfere only with female gamete formation (S1 Table.
Malaria Box HeatMap, column BV and BW)26 and that of
compound 2 to impact on female (S1 Table. Malaria Box
HeatMap,10 column BV and BW)26 and male (S1 Table.
Malaria Box HeatMap,10 column BZ and CA)29 gamete
formation, might have contributed to the reduced ESS
counts found in our assays.
At primary screening (50µg/mL), compounds 1, 2 and
3 showed more than 80% inhibitory activity specifically on
ookinete formation, ie on the process of building up the
elongated motile ookinete from the round zygote stage.
Similarly, compounds 5, 6 and 8 exhibited more than 70%
inhibition against ookinete development. Differential
counts on Giemsa thin smears prepared from assay plates
(after 24 h incubation with compounds 1, 2, 3, 5, 6, 8)
revealed various morphological alterations of post-zygotic
forms such as irregular shape, jagged borders, enlarged
hemozoin vacuoles and absence of a condensed nucleus.
Given this pattern of multiple cellular alterations most
likely caused by downstream effects of a primary com-
pound action, it is impossible to raise any hypothesis on
the mode of actions. However, what these morphological
alterations recall is the biological complexity of ookinete
maturation, a process that includes among other the assem-
bly of the apicomplexan organelles and of a cytoskeleton
allowing the slender mature ookinete to move, offering
multiple targets for possible drug interference.8
In summary, this work and the results obtained by other
studies published in the Van Voorhis review10 allow to estab-
lish for compounds 1, 2, and 3 (MMV000662, MMV006429
and MMV00064) a prominent multi-stage activity against
Plasmodium: they are active against asexual blood stages,
against developing (I–IV) and mature (stage V) gametocytes,
they inhibit female gamete formation (also male in the case of
compound 2) and interfere with the early sporogonic develop-
ment, including ookinete maturation. Moreover, this study
identified the 1,2,3,4-tetrahydroisoquinoline-4-carboxamide
chemical skeleton (9 in Figure 4), including compounds 1–3,
as having attractive, fragment-based, druggable chemical
properties as reported in previous studies.18 The 1,2,3,4-tetra-
hydroisoquinoline skeleton is also encountered in a number of
drugs in clinical use such as tubocurarine, nomifensine, diclo-
fensine and quinapril. Due to its distinct geometrical confor-
mation and biological activity, 1,2,3,4-tetrahydroisoquinoline
has been introduced into several molecules, which target
diverse enzymes or receptors, leading to antineoplastic
drugs, nitric oxide (NO) inhibitors, histamine H3 antagonists,
serotonin reuptake inhibitors, α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid (AMPA) receptor antagonists, mul-
tidrug resistance (MDR) reversals, γ-secretase inhibitors,
kinase insert domain-containing receptor (KDR) inhibitors,
and antidiabetic drugs.18
Regarding antimalarial activity, a recent publication by
Delves and colleagues identified various transmission-
blocking compounds belonging to the tetrahydroisoquino-
line family.31 In particular, TCMDC-125849 (TCAMS
library, GSK) was active in the Pb ODA with an IC50 of
268 nM and decreased oocyst density in the Pb standard
membrane feeding assay by 71.4% at 1 µM. Thus, our
results together with the latter findings support the key
importance of this skeleton that might allow successful
drug development for the control of malaria and various
other diseases.
Conclusion and Recommendation
Thanks to the Malaria Box initiative and the efficient open
access policy of MMV, this study was able to contribute to
a more comprehensive phenotypic characterization of eight
HN
NH2O
9
12
3 4
Figure 4 1,2,3,4-tetrahydroisoquinoline-4-carboxamide (9) chemical skeleton,
including compounds 1–3, as having attractive fragment-like druggable chemical
properties.
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antimalarial compounds (1. MMV000662, 2. MMV006429,
3. MMV000642, 4. MMV019266, 5. MMV665876, 6.
MMV006767, 7. MMV085583, 8. MMV665827), selected
as potential inhibitors of polyamine biosynthesis. Three out
of the eight compounds, namely 1. MMV000662; 2.
MMV006429; 3. MMV000642, confirmed to possess anti-
malarial multi-stage activity, interfering with the parasite
asexual blood stages, the gametocytes and the insect early
sporogonic stages. Interestingly, this broad spectrum activity
appears to remain restricted to the different stages of
Plasmodium spp.: none of the three compounds was active
against the taxonomically related apicomplexan protozoans
Toxoplasma, Cryptosporidium, Babesia and Theileria spp.
Given that the three compounds were also inactive against
other protozoan (Entamoeba) parasites, various nematodes
and Schistosoma spp.,10 these compounds can be excluded as
potential multi-disease agents for mass treatment campaigns.
In relation to the recent MMVantimalarial drug policies
and attempts to orient research through the conceptualization
of Target Product Profiles (TPP) and Target Candidate
Profiles (TCP),4 compounds 1, 2 and 3 fit with the TCP 5
and TCP 6, that focus on transmission-blocking drugs, and
TPP 1, that defines drug combinations.4 In fact, the com-
pounds display an interesting transmission-blocking profile,
given by their capacity to interfere with various transmissible
stages, in the vertebrate host as well as in the insect vector.
This sort of “backed up” transmission-blocking profile
enhances the probability to hit a single parasite and hence
to achieve interruption of transmission. In addition, given the
multi-stage effects of the compounds, that includes activity
against the asexual blood stages responsible for the disease,
they can be considered potentially valid agents to be included
in combination drug formulations. On the basis of the out-
lined promising activity of compounds 1, 2, and 3, we con-
sider them worth of further structural optimization.
Derivative design may be guided by the fact that all the
three most active compounds possess a 1,2,3,4-tetrahydroi-
soquinoline-4-carboxamide chemical skeleton substituted at
N-2, C-3 and C-4.
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